Anti-idiotypic Antibodies

Custom Anti-idiotypic Antibodies

  • Rapid in vitro high-affinity custom anti-drug antibody generation
  • Guided selection strategies for anti-idiotypic antibody generation
  • Flexible formats; Fab antibodies can be converted into other Fab formats or full length human immunoglobulins
  • Secure and unlimited supply

Antibody based drugs represent some of the most widely used therapies in medicine today. Clinical studies into therapeutic chimeric, humanized or human antibodies  require specialist detection tools which have the ability to differentiate between the drug itself and naturally occurring immunoglobulin, which will always be present in human samples. HuCAL recombinant antibody production supports therapeutic drug development efficiently with highly specific, monoclonal, anti-idiotypic antibodies.

  • HuCAL® anti-idiotypic antibodies are ideal for preclinical research and generation of data to support the development of human antibody drugs.
  • Their recombinant origin ensures:
    • an unlimited, secure and batch-to-batch consistent supply of assay tools for extensive clinical studies
    • highly specific, fully human antibodies against the drug/drug-target complexes 

Watch our video on 'The Development of Recombinant Anti-Idiotypic Antibodies for PK/PD and Immunogenicity Assays'

 

Ready-made Anti-Idiotypic Antibodies 

Rituximab (Rituxan®)   
  • High affinity & ultra-high affinity antibodies (down to low picomolar affinities)
  • Sensitivity in the low ng/mL range in 10% human serum
  • Monovalent Fab and IgG1 antibody formats
  • Additional formats/isotypes available upon request
Trastuzumab (Herceptin®)
Alemtuzumab (Campath®)
Bevacizumab (Avastin®)
Adalimumab (HUMIRA®)
Ustekinumab (Stelara®)
Cetuximab (ERBITUX®)
Infliximab (Remicade®)*

*Anti Infliximab is not available to purchase in the U.S.A.

HuCAL® is a registered trademark of MorphoSys AG. Rituxan® is a registered trademark of Biogen Idec, Inc. USA. Remicade® is a registered trademark of Janssen Biotech, Inc. USA. Campath® is a registered trademark of Genzyme Corporation. Herceptin® is a registered trademark of Genentech, Inc. USA. Avastin® is a registered trademark of Genentech, Inc. USA. Stelara® is a registered trademark of Janssen Biotech, Inc. USA. HUMIRA® is a registered trademark of Abbott Laboratories.